Investigating how platinum chemotherapy affects immune responses in small cell lung cancer
Official title: Platinum-induced lipid reprogramming and tumor immune microenvironment in SCLC
Funded at University of Texas Hlth Science Center · NIH-10868735 · Data updated 2026-11-12
This study is looking at how a common chemotherapy treatment affects the immune system in patients with small cell lung cancer, with the goal of finding better ways to help the body fight the cancer using immune therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $334,978 |
| NIH project number | 5R01CA269782-03 |
| Project ID | NIH-10868735 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with small cell lung cancer who are undergoing or considering treatment with platinum-based chemotherapy.
✕Less likely to help
Patients with other types of lung cancer or those who are not receiving platinum-based chemotherapy may not benefit from this research.
What this research studies
This research focuses on small cell lung cancer (SCLC), a highly aggressive form of lung cancer with a very low survival rate. It aims to understand how platinum-based chemotherapy influences the immune environment of tumors and the effectiveness of immune checkpoint inhibitors, which are treatments designed to enhance the body's immune response against cancer. The study will explore the role of dendritic cells, which are crucial for initiating immune responses, and how they may become dysfunctional in the presence of tumor-derived substances. By examining these interactions, the research seeks to uncover mechanisms that could improve treatment outcomes for patients with SCLC.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for small cell lung cancer, potentially enhancing patient survival rates.
How similar studies have gone: Previous research has shown promising results in understanding immune responses in cancer treatment, but this specific approach to SCLC is relatively novel.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Jin, Lingtao — University of Texas Hlth Science Center
- Study coordinator: Jin, Lingtao
Related research
Other NIH-funded projects on the same topics.
-
Role of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC in the Immunotherapy Era
This project looks at whether giving twice-daily radiotherapy for limited-stage small cell lung cancer still helps patients today who are also getting immunotherapy.
-
SCLC model creation and therapy testing
A cancer research program using mouse models and engineered human and mouse cells to study small cell lung cancer and test potential treatments.
-
Impact of genetic changes on SCLC subtypes and treatment response
This project explores how specific genetic changes in small cell lung cancer (SCLC) affect the disease and how it responds to targeted drugs.
-
Repair mechanisms for DNA lesions in small cell lung cancer
Researchers are studying how cancer cells with small cell lung cancer respond or become resistant to treatment by looking at the ways DNA damage is repaired.
-
Understanding how replication stress affects a hard-to-treat breast cancer gene patients may carry
This grant explores how certain breast cancer gene defects interact with replication stress to influence cancer cell survival and treatment resistance, with potential implications for therapies in patients with BRCA2-related breast cancer.
-
Replication Stress Sensing Defects in Small Cell Lung Cancer
A study in people might not be involved directly, but it aims to understand why a common lung cancer responds poorly to therapy over time by examining how cancer cells handle replication stress.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.